Skip to main content
Journal cover image

Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression

Publication ,  Journal Article
Jackson, DO; Peace, KM; Hale, DF; Vreeland, TJ; Choy, G; Nejadnik, B; Greene, JM; Schneble, EJ; Berry, JS; Trappey, AF; Hardin, MO; Holmes, JP ...
Published in: Annals of Oncology
October 1, 2016

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Annals of Oncology

DOI

EISSN

1569-8041

ISSN

0923-7534

Publication Date

October 1, 2016

Volume

27

Start / End Page

vi366

Related Subject Headings

  • Oncology & Carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Jackson, D. O., Peace, K. M., Hale, D. F., Vreeland, T. J., Choy, G., Nejadnik, B., … Peoples, G. E. (2016). Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression. Annals of Oncology, 27, vi366. https://doi.org/10.1093/annonc/mdw378.23
Jackson, D. O., K. M. Peace, D. F. Hale, T. J. Vreeland, G. Choy, B. Nejadnik, J. M. Greene, et al. “Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression.” Annals of Oncology 27 (October 1, 2016): vi366. https://doi.org/10.1093/annonc/mdw378.23.
Jackson DO, Peace KM, Hale DF, Vreeland TJ, Choy G, Nejadnik B, et al. Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression. Annals of Oncology. 2016 Oct 1;27:vi366.
Jackson, D. O., et al. “Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression.” Annals of Oncology, vol. 27, Oct. 2016, p. vi366. Scopus, doi:10.1093/annonc/mdw378.23.
Jackson DO, Peace KM, Hale DF, Vreeland TJ, Choy G, Nejadnik B, Greene JM, Schneble EJ, Berry JS, Trappey AF, Hardin MO, Clifton GT, Herbert GS, Mittendorf E, Holmes JP, Peoples GE. Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression. Annals of Oncology. 2016 Oct 1;27:vi366.
Journal cover image

Published In

Annals of Oncology

DOI

EISSN

1569-8041

ISSN

0923-7534

Publication Date

October 1, 2016

Volume

27

Start / End Page

vi366

Related Subject Headings

  • Oncology & Carcinogenesis
  • 1112 Oncology and Carcinogenesis